Literature DB >> 23551036

Hyperprolactinaemia associated with increased thyroid volume and autoimmune thyroiditis in patients with prolactinoma.

Muyesser Sayki Arslan1, Mustafa Sahin, Oya Topaloglu, Esra Tutal, Melia Karakose, Askin Gungunes, Erman Cakal, Mustafa Ozbek, Tuncay Delibasi.   

Abstract

OBJECTIVE: The aim of this investigation was to evaluate the effects of hyperprolactinaemia on thyroid function, volume and nodularity in patients with prolactinoma. CONTEXT: Hyperprolactinaemia has been associated with various autoimmune diseases; however, the data on the correlation between the level of prolactin (PRL) and thyroid disorders have not been adequately clarified.
DESIGN: Case-control study. PATIENTS: Forty-eight subjects with new diagnosis of hyperprolactinaemia (group 1) and 39 subjects undergoing treatment for prolactinoma (group 2) were recruited from our outpatient clinic. Fifty-two healthy subjects were included as a control group (group 3). MEASUREMENTS: The serum PRL, thyroid-stimulating hormone (TSH), thyroxine (free T4), thyroidal microsome (anti-TPO) and antithyroglobulin antibodies (TgAb) levels were evaluated, and ultrasonographic thyroid volume was calculated.
RESULTS: The frequencies of positive anti-TPO and TgAb were significantly higher in group 1 than in groups 2 and 3 (P = 0·008). Also, the percentage of patients with thyroid heterogeneity were significantly higher in groups 1 and 2 than in group 3 (P < 0·05). The percentage of patients with thyroid nodules were higher in group 1 than in groups 2 and 3 (p1-2 = 0·03, p1-3 = 0·05 and p2-3 = 0·637). The mean thyroid volume was significantly higher in group 1 (P = 0·001), and a positive correlation was found between thyroid volume and the level of PRL (r = 0·616; P = 0·0001). Prolactin had a significant effect on the total volume according to stepwise multiple linear regression analysis (adjusted R(2) is 0·268; P < 0·0001).
CONCLUSIONS: Patients with hyperprolactinaemia have significantly increased thyroid volume, thyroid autoimmunity and nodule prevalence.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23551036     DOI: 10.1111/cen.12217

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study.

Authors:  Atanaska Elenkova; Iliana Аtanasova; Georgi Кirilov; Еmil Natchev; Ralitza Ivanova; Roussanka Кovatcheva; Silvia Vandeva; Dimitar Tcharaktchiev; Sabina Zacharieva
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

2.  Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenomas.

Authors:  V Larouche; J A Correa; P Cassidy; C Beauregard; N Garfield; J Rivera
Journal:  Pituitary       Date:  2016-04       Impact factor: 4.107

3.  Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents.

Authors:  Lucia Margari; Emilia Matera; Maria G Petruzzelli; Marta Simone; Anna L Lamanna; Adriana Pastore; Vincenzo O Palmieri; Francesco Margari
Journal:  Int Clin Psychopharmacol       Date:  2015-03       Impact factor: 1.659

4.  A rare case of Cushing's disease concurrent with papillary thyroid carcinoma.

Authors:  Zahra Kashi; Omid Emadian; Marzieh Movahedirad
Journal:  Caspian J Intern Med       Date:  2021

5.  Primary thyroid disorders in patients with endogenous hypercortisolism: an observational study.

Authors:  Eda Demir Onal; Muhammed Sacikara; Fatma Saglam; Reyhan Ersoy; Bekir Cakir
Journal:  Int J Endocrinol       Date:  2014-05-05       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.